Chronic Myelogenous Leukemia

Clinical Trials

Below is a list of Chronic Myelogenous Leukemia clinical trials from the clinical trials database at Mayo Clinic.

This list includes only trials about which Mayo researchers choose to publish information. Mayo Clinic may be conducting other trials which are not in this database. Mayo's clinical trials include experimental treatments, often unavailable elsewhere, which frequently lead to improved patient care for people worldwide. Patients should ask their doctor at Mayo about clinical trials appropriate for their situation.

A Phase 2b Study of Molecular Responses to Imatinib (Gleevec) at Standard or Increased Doses, or Dasatinib (BMS-354825) (NSC-732517) for Previously Untreated Patients with Chronic Myelogenous Leukemia (CML) in Chronic Phase
This study is being done to:
- Find out what effects (good and bad) regular or increased doses of imatinib or
dasatinib has on a patient and their Chronic Myelogenous Leukemia (CML)
- Find out if giving a larger dose of imatinib will have any effect on the patient and their
CML or if giving the drug, dasatinib, will have any effect on the patient and their
CML.
- Find out which treatment works the best for CML in chronic phase when comparing
imatinib treatment at standard doses with higher doses of imatinib treatment and
with dasatinib treatment.
Read more

Phase 2 Study of the Subcutaneous Administration of Homoharringtonine (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL Gene Mutation
Patients are asked to take part in this research study because they have chronic myeloid leukemia (CML) and a mutation (change) in a particular gene (T315I gene) found in their bone marrow and blood cells. CML is a blood disorder related to high white blood cell counts and platelet counts, anemia (decreased red blood cells), bleeding problems or bruising (due to low platelet counts, which circulate in the blood and prevent bleeding), fatigue (tiredness) and increased risk of infection. The T315I gene mutation occurs in a small number of patients with CML. Because of this mutation, patients may not respond to some treatments for CML. The purpose of this clinical research study is to determine the safety of the investigational drug homoharringtonine (HHT) and its potential effectiveness for the treatment of CML in patients who have the T315I mutation.

The drug used in this study is considered investigational, which means it has either not been approved by the U.S. Food and Drug Administration (FDA) for routine clinical use or for the use described in this study. However the FDA has allowed the use of this drug/device in this research study.
Read more

Phase II Study with Azacitidine with or without (the Histone Deacetylase Inhibitor) MS-275 for the Treatment of Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CML) and Acute Myeloid Leukemia (AML)
The purpose of this study is to find out what effects, good or bad, one of two treatment programs has on a patient and their bone marrow disorder. One treatment program consists of a new dose and schedule of a drug called Azacitidine, which is approved for the treatment of myelodysplastic syndrome (MDS). The other treatment program includes the same dose and schedule of azacitidine in combination with a new drug known as MS-275. In this study patients will get either azacitidine alone, or azacitidine plus MS-275. Patients will not get both treatment
programs.

MS-275 is investigational and has not been approved by the U.S. Food and Drug Administration (FDA) for use in this cancer.
Read more